Feasibility of HPV Testing With Mail-delivered Sample Collection Kits (NCT07087145)
Persistent Oral HPV Among Diverse PLWH: A Pilot Study to Evaluate the Feasibility and Acceptability of Testing for Oral HPV DNA Infection With Mail-delivered Sample Collection Kits
🩺 Plain-English Summary (8th-Grade Level)
People living with human immunodeficiency virus (PLWH) have an estimated 1.6-6.0 times increased risk of developing oropharyngeal cancer (OPC) compared with individuals in the general population. 70% of OPCs are caused by human papillomavirus (HPV), and PLWH also have an increased prevalence of oral HPV infection. Disparities by race/ethnicity also include a later stage of diagnosis and less frequent cancer-directed treatment for members of ethnic minority groups. There is little known regarding the racial/ethnic differences in oral HPV infection, persistence of oral HPV infection, or progression of oral HPV infection to OPC among PLWH. This is an observational, prospective cohort study to investigate the feasibility of alternative sample collection methods for HPV testing among PLWH.
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco — San Francisco, California
Age range: 35 Years
🧪 Interventions in This Study
- Mail-based Saliva Sample Kit (DIAGNOSTIC_TEST)
- Study-related Surveys (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of California, San Francisco — San Francisco, California
📞 Contact the Study Coordinator
Phone: (415) 949-8336
Email: William.Juarez@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HPV Infection
- Intradermal, Fractional Dose of HPV Vaccines: — Seattle, Washington
- Immunogenicity of Fractional Dose of the HPV Vaccines — Seattle, Washington
- An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen — Boston, Massachusetts
- Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV — Rockville, Maryland
- PCOM2 - The Physician Communication Intervention, Version 2.0 — Aurora, Colorado
Explore by condition: All HPV Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.